h-1337
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 15, 2018 (NCT03452033)
Timeline
Indications
Mechanism of action
- Protein kinase N2INHIBITOR
PKN2 inhibitor
- Polycystin-1INHIBITOR
PKD1 inhibitor
LRRK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06572397 | Phase 1 | Sep 16, 2024 | D. Western Therapeutics Institute, Inc. |
| NCT05913232 | Phase 2 | Aug 28, 2023 | D. Western Therapeutics Institute, Inc. |
| NCT03452033 | Phase 2 | Mar 15, 2018 | Allysta Pharmaceutical |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| D. Western Therapeutics Institute, Inc. | For profit | 2 | 2 | 2 | 2023 |
| Allysta Pharmaceutical | For profit | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1